Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-10 06:01 am Purchase | 2026-02-09 | 13D | CASI Pharmaceuticals, Inc. CASI | WEI-WU HE, Ph.D. | 13,965,535 45.400% | 5,000,000 (+55.77%) | Filing History |
| 2026-01-29 7:21 pm Purchase | 2026-01-27 | 13D | CASI Pharmaceuticals, Inc. CASI | WEI-WU HE, Ph.D. | 8,965,535 34.800% | 5,000,000 (+126.09%) | Filing History |
| 2026-01-20 09:33 am Unchanged | 2025-09-30 | 13D | CASI Pharmaceuticals, Inc. CASI | Ho Chi Sing | 992,638 4.800% | 0 (Unchanged) | Filing History |
| 2026-01-20 09:30 am Purchase | 2025-09-30 | 13D | CASI Pharmaceuticals, Inc. CASI | SPARKLE BYTE LTD | 1,019,852 5.000% | 1,019,852 (New Position) | Filing History |
| 2026-01-09 06:03 am Unchanged | 2026-01-09 | 13D | CASI Pharmaceuticals, Inc. CASI | WEI-WU HE, Ph.D. | 3,965,535 19.100% | 0 (Unchanged) | Filing History |
| 2025-12-18 06:01 am Purchase | 2025-12-18 | 13D | CASI Pharmaceuticals, Inc. CASI | WEI-WU HE, Ph.D. | 3,965,535 19.100% | 230,000 (+6.16%) | Filing History |
| 2025-12-17 4:15 pm Purchase | 2025-12-16 | 13D | CASI Pharmaceuticals, Inc. CASI | Panacea Innovation Limited | 4,651,527 22.500% | 989,956 (+27.04%) | Filing History |
| 2025-11-26 4:05 pm Purchase | 2025-09-30 | 13G | CASI Pharmaceuticals, Inc. CASI | Chen Zhenfeng | 2,255,636 11.000% | 2,255,636 (New Position) | Filing History |
| 2025-11-14 4:05 pm Purchase | 2025-09-30 | 13G | CASI Pharmaceuticals, Inc. CASI | Foresite Capital Fund VI LP | 979,956 6.300% | 192,835 (+24.50%) | Filing History |
| 2025-09-26 6:45 pm Purchase | 2025-09-26 | 13D | CASI Pharmaceuticals, Inc. CASI | Panacea Innovation Limited | 3,661,571 19.900% | 3,661,571 (New Position) | Filing History |
| 2025-08-12 4:05 pm Sale | 2025-06-30 | 13G | CASI Pharmaceuticals, Inc. CASI | Foresite Capital Fund VI LP | 787,121 5.100% | -522,262 (-39.89%) | Filing History |
| 2025-07-23 09:39 am Purchase | 2025-06-30 | 13G | CASI Pharmaceuticals, Inc. CASI | Huang James | 2,161,571 13.800% | 726,571 (+50.63%) | Filing History |
| 2025-06-20 4:30 pm Purchase | 2025-06-16 | 13D | CASI Pharmaceuticals, Inc. CASI | WEI-WU HE, Ph.D. | 3,735,535 23.800% | 477,644 (+14.66%) | Filing History |
| 2025-02-03 8:17 pm Purchase | 2024-12-30 | 13D | CASI Pharmaceuticals, Inc. CASI | Ho Chi Sing | 992,638 6.400% | 992,638 (New Position) | Filing History |
| 2024-10-29 4:05 pm Purchase | 2024-09-30 | 13G | CASI Pharmaceuticals, Inc. CASI | Huang James | 1,435,000 9.200% | 305,000 (+26.99%) | Filing History |
| 2024-08-12 08:27 am Purchase | 2024-07-15 | 13D | CASI Pharmaceuticals, Inc. CASI | WEI-WU HE, Ph.D. | 3,257,891 20.940% | 420,000 (+14.80%) | Filing History |
| 2024-07-25 8:48 pm Purchase | 2024-07-15 | 13G | CASI Pharmaceuticals, Inc. CASI | Venrock Healthcare Capital Partners III, L.P. | 1,507,040 9.990% | 1,507,040 (New Position) | Filing History |
| 2024-06-20 9:00 pm Purchase | 2024-06-10 | 13G | CASI Pharmaceuticals, Inc. CASI | Foresite Capital Fund VI LP | 1,309,383 9.800% | 1,309,383 (New Position) | Filing History |
| 2024-06-11 4:10 pm Sale | 2024-06-10 | 13G | CASI Pharmaceuticals, Inc. CASI | Huang James | 1,130,000 8.400% | -1,565,000 (-58.07%) | Filing History |
| 2024-01-26 08:31 am Purchase | 2024-01-25 | 13G | CASI Pharmaceuticals, Inc. CASI | Huang James | 2,695,000 19.990% | 268,000 (+11.04%) | Filing History |